Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy

Research output: Contribution to journalArticle

Abstract

While there is general agreement on the favorable impact of immunosuppression in eosinophilic, granulomatous, giant cell myocarditis, in lymphocytic myocarditis associated with connective tissue disorders and with rejection of the transplanted heart, its therapeutic role for lymphocytic inflammatory cardiomyopathy (ICM), is still debated. Previous retrospective studies reported a relevant (≥10% left ventricular ejection fraction; LVEF) clinical benefit in 90% of patients with virus-negative ICM and no response or cardiac impairment in 85% of patients with virus-positive ICM following immunosuppression. Other studies identified cardiomyocyte HLA upregulation as an additional indicator of ICM susceptibility to immunosuppressive therapy. Recently, in a single-center randomized prospective double-blind trial using a combination of prednisone (1 mg/kg a day for 4 weeks followed by 0.33 mg/kg a day for 5 months) and azathioprine (2 mg/kg a day for 6 months) in addition to supportive treatment in 85 virus-negative ICM patients, a significant improvement was reported in LVEF and a significant reduction in left ventricular dimensions in 88% of 43 treated patients compared with 42 patients receiving placebo who showed a cardiac impairment in 83% of cases (TIMIC study). These data confirm the efficacy of immunosuppression in virus-negative ICM. Lack of response in 12% of cases suggests the presence of viruses that were not screened for or mechanisms of damage and inflammation not susceptible to immunosuppression. Recovery of cardiac function in responders to immunosuppression was associated with inhibition of cardiomyocyte death, an increase in cell proliferation and with newly synthesized contractile material.

Original languageEnglish
Pages (from-to)18-21
Number of pages4
JournalHeart and Metabolism
Issue number62
Publication statusPublished - 2014

Fingerprint

Immunosuppressive Agents
Cardiomyopathies
Immunosuppression
Viruses
Myocarditis
Cardiac Myocytes
Therapeutics
Recovery of Function
Azathioprine
Giant Cells
Prednisone
Stroke Volume
Connective Tissue
Up-Regulation
Retrospective Studies
Placebos
Cell Proliferation
Inflammation

Keywords

  • Heart failure
  • Immunosuppressive therapy
  • Myocarditis
  • Recovery of function
  • Viruses

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy. / Frustaci, Andrea; Chimenti, Cristina.

In: Heart and Metabolism, No. 62, 2014, p. 18-21.

Research output: Contribution to journalArticle

@article{3ed3d37f810f4ba8b6604bdec98957da,
title = "Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy",
abstract = "While there is general agreement on the favorable impact of immunosuppression in eosinophilic, granulomatous, giant cell myocarditis, in lymphocytic myocarditis associated with connective tissue disorders and with rejection of the transplanted heart, its therapeutic role for lymphocytic inflammatory cardiomyopathy (ICM), is still debated. Previous retrospective studies reported a relevant (≥10{\%} left ventricular ejection fraction; LVEF) clinical benefit in 90{\%} of patients with virus-negative ICM and no response or cardiac impairment in 85{\%} of patients with virus-positive ICM following immunosuppression. Other studies identified cardiomyocyte HLA upregulation as an additional indicator of ICM susceptibility to immunosuppressive therapy. Recently, in a single-center randomized prospective double-blind trial using a combination of prednisone (1 mg/kg a day for 4 weeks followed by 0.33 mg/kg a day for 5 months) and azathioprine (2 mg/kg a day for 6 months) in addition to supportive treatment in 85 virus-negative ICM patients, a significant improvement was reported in LVEF and a significant reduction in left ventricular dimensions in 88{\%} of 43 treated patients compared with 42 patients receiving placebo who showed a cardiac impairment in 83{\%} of cases (TIMIC study). These data confirm the efficacy of immunosuppression in virus-negative ICM. Lack of response in 12{\%} of cases suggests the presence of viruses that were not screened for or mechanisms of damage and inflammation not susceptible to immunosuppression. Recovery of cardiac function in responders to immunosuppression was associated with inhibition of cardiomyocyte death, an increase in cell proliferation and with newly synthesized contractile material.",
keywords = "Heart failure, Immunosuppressive therapy, Myocarditis, Recovery of function, Viruses",
author = "Andrea Frustaci and Cristina Chimenti",
year = "2014",
language = "English",
pages = "18--21",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Imprimerie Jouve",
number = "62",

}

TY - JOUR

T1 - Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy

AU - Frustaci, Andrea

AU - Chimenti, Cristina

PY - 2014

Y1 - 2014

N2 - While there is general agreement on the favorable impact of immunosuppression in eosinophilic, granulomatous, giant cell myocarditis, in lymphocytic myocarditis associated with connective tissue disorders and with rejection of the transplanted heart, its therapeutic role for lymphocytic inflammatory cardiomyopathy (ICM), is still debated. Previous retrospective studies reported a relevant (≥10% left ventricular ejection fraction; LVEF) clinical benefit in 90% of patients with virus-negative ICM and no response or cardiac impairment in 85% of patients with virus-positive ICM following immunosuppression. Other studies identified cardiomyocyte HLA upregulation as an additional indicator of ICM susceptibility to immunosuppressive therapy. Recently, in a single-center randomized prospective double-blind trial using a combination of prednisone (1 mg/kg a day for 4 weeks followed by 0.33 mg/kg a day for 5 months) and azathioprine (2 mg/kg a day for 6 months) in addition to supportive treatment in 85 virus-negative ICM patients, a significant improvement was reported in LVEF and a significant reduction in left ventricular dimensions in 88% of 43 treated patients compared with 42 patients receiving placebo who showed a cardiac impairment in 83% of cases (TIMIC study). These data confirm the efficacy of immunosuppression in virus-negative ICM. Lack of response in 12% of cases suggests the presence of viruses that were not screened for or mechanisms of damage and inflammation not susceptible to immunosuppression. Recovery of cardiac function in responders to immunosuppression was associated with inhibition of cardiomyocyte death, an increase in cell proliferation and with newly synthesized contractile material.

AB - While there is general agreement on the favorable impact of immunosuppression in eosinophilic, granulomatous, giant cell myocarditis, in lymphocytic myocarditis associated with connective tissue disorders and with rejection of the transplanted heart, its therapeutic role for lymphocytic inflammatory cardiomyopathy (ICM), is still debated. Previous retrospective studies reported a relevant (≥10% left ventricular ejection fraction; LVEF) clinical benefit in 90% of patients with virus-negative ICM and no response or cardiac impairment in 85% of patients with virus-positive ICM following immunosuppression. Other studies identified cardiomyocyte HLA upregulation as an additional indicator of ICM susceptibility to immunosuppressive therapy. Recently, in a single-center randomized prospective double-blind trial using a combination of prednisone (1 mg/kg a day for 4 weeks followed by 0.33 mg/kg a day for 5 months) and azathioprine (2 mg/kg a day for 6 months) in addition to supportive treatment in 85 virus-negative ICM patients, a significant improvement was reported in LVEF and a significant reduction in left ventricular dimensions in 88% of 43 treated patients compared with 42 patients receiving placebo who showed a cardiac impairment in 83% of cases (TIMIC study). These data confirm the efficacy of immunosuppression in virus-negative ICM. Lack of response in 12% of cases suggests the presence of viruses that were not screened for or mechanisms of damage and inflammation not susceptible to immunosuppression. Recovery of cardiac function in responders to immunosuppression was associated with inhibition of cardiomyocyte death, an increase in cell proliferation and with newly synthesized contractile material.

KW - Heart failure

KW - Immunosuppressive therapy

KW - Myocarditis

KW - Recovery of function

KW - Viruses

UR - http://www.scopus.com/inward/record.url?scp=84899549589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899549589&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84899549589

SP - 18

EP - 21

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 62

ER -